Emerging role of HMGB1 in lung diseases: friend or foe

被引：95

作者：

Ding, Junying ^{[1
]}

Cui, Xuran ^{[1
]}

Liu, Qingquan ^{[1
]}

机构：

[1] Capital Med Univ, Beijing Res Inst TCM, Beijing Key Lab Basic Study Tradit Chinese Med TC, Beijing Hosp TCM, Beijing, Peoples R China

来源：

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE | 2017年 / 21卷 / 06期

基金：

中国国家自然科学基金;

关键词：

high-mobility group box 1; receptor for advanced glycation end product; lung diseases; target therapy; GROUP BOX 1; GLYCATION END-PRODUCTS; CHROMATIN PROTEIN HMGB1; TISSUE-DAMAGE; INFLAMMASOME ACTIVATION; PULMONARY-FIBROSIS; CYTOKINE ACTIVITY; CELL RECRUITMENT; TARGETING HMGB1; DRUG TARGET;

D O I：

10.1111/jcmm.13048

中图分类号：

Q2 [细胞生物学];

学科分类号：

071013 [干细胞生物学];

摘要：

Lung diseases remain a serious problem for public health. The immune status of the body is considered to be the main influencing factor for the progression of lung diseases. HMGB1 (high-mobility group box 1) emerges as an important molecule of the body immune network. Accumulating data have demonstrated that HMGB1 is crucially implicated in lung diseases and acts as independent biomarker and therapeutic target for related lung diseases. This review provides an overview of updated understanding of HMGB1 structure, release styles, receptors and function. Furthermore, we discuss the potential role of HMGB1 in a variety of lung diseases. Further exploration of molecular mechanisms underlying the function of HMGB1 in lung diseases will provide novel preventive and therapeutic strategies for lung diseases.

引用

页码：1046 / 1057

页数：12

共 138 条

[1]

Reduction in Serum High Mobility Group Box-1 Level by Polymyxin B-Immobilized Fiber Column in Patients with Idiopathic Pulmonary Fibrosis with Acute Exacerbation [J].